Blog Financial Times: Vaccine makers race to fix vaccine supply issues January 12, 2021 GreenLight Biosciences explain to the Financial Times the vaccine supply issues for a Covid-19 vaccine. GreenLight Biosciences spoke to the Financial Times about the vaccine supply issues for the Covid-19 vaccine. An extract from the article is below: Andrey Zarur, head of GreenLight Biosciences, said ingredients stockpiled ahead of vaccine approvals would supply the first 1bn-2bn doses, but bottlenecks would emerge after that.Challenges include sourcing items ranging from DNA molecules to lipid nanoparticles — the microscopic oily droplets that deliver the vaccine’s active mRNA ingredient — he said. “Pfizer and Moderna have kicked off conversations with suppliers like Trilink, Aldevron and New England Biolabs to answer the challenge, but it will require government and deep cross-industry co-operation to make it work.” Read the full article here. Find out more about how GreenLight manufactures RNA here. More of Greenlight Bioscience in the news: STAT: Businesses across the vaccine supply chain must work together to make Covid-19 vaccines Financial Times: Get vaccine new variant ready Mail Online: Vaccine roll out issues Financial Times: Vaccine makers race to fix vaccine supply issues Technology Review: What are the Pfizer covid-19 vaccine ingredients? Financial Times: Vaccine manufacturing delays leave UK with fewer vaccines than hoped